Results 181 to 190 of about 2,262 (198)

Asunaprevir/daclatasvir

Reactions Weekly, 2020
openaire   +1 more source

Asunaprevir

Drugs of the Future, 2012
openaire   +1 more source

Asunaprevir/daclatasvir

Reactions Weekly, 2019
openaire   +2 more sources

Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Journal of Medical Virology, 2016
Norio Akuta, Hitomi Sezaki, Tetsuya Hosaka   +2 more
exaly  

Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients

Journal of Gastroenterology and Hepatology (Australia), 2016
Takayoshi Itô, Yoshito Itoh, Yoshiyasu Karino   +2 more
exaly  

Characterization of ADME properties of [14C]asunaprevir (BMS-650032) in humans

Xenobiotica, 2016
John Easter, Hao Jiang, Ramaswamy Iyer   +2 more
exaly  

Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV‐Infected Subjects

Clinical Pharmacology in Drug Development, 2019
Tushar Garimella
exaly  

Real‐world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus‐infected cirrhosis patients

Journal of Gastroenterology and Hepatology (Australia), 2017
Masataka Tsuge, Michio Imamura, Tomokazu Kawaoka   +2 more
exaly  

A highly sensitive and selective LC–MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies

Journal of Pharmaceutical and Biomedical Analysis, 2016
Hamza Kandoussi, Naiyu Zheng, Mark E Arnold   +2 more
exaly  

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection

Journal of Comparative Effectiveness Research, 2015
Keith A Betts, Yan Song, Junlong Li
exaly